Shengnan Du

591 total citations
24 papers, 466 citations indexed

About

Shengnan Du is a scholar working on Molecular Biology, Oncology and Surgery. According to data from OpenAlex, Shengnan Du has authored 24 papers receiving a total of 466 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 7 papers in Oncology and 4 papers in Surgery. Recurrent topics in Shengnan Du's work include Nitric Oxide and Endothelin Effects (2 papers), Ion Transport and Channel Regulation (2 papers) and Cancer therapeutics and mechanisms (2 papers). Shengnan Du is often cited by papers focused on Nitric Oxide and Endothelin Effects (2 papers), Ion Transport and Channel Regulation (2 papers) and Cancer therapeutics and mechanisms (2 papers). Shengnan Du collaborates with scholars based in China, United States and Sweden. Shengnan Du's co-authors include Youfei Guan, Xiaoyan Zhang, Xiao Jia, Yifei Miao, Jan-Ακε Gustafsson, Wen Su, Shizheng Huang, Min Gao, Lihong Chen and Feng Zheng and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Hepatology and Marine Pollution Bulletin.

In The Last Decade

Shengnan Du

22 papers receiving 460 citations

Peers

Shengnan Du
Qian Yu China
Chakradhari Sharan United States
Hüseyin Sönmez Türkiye
Antônio Ricardo de Toledo Gagliardi Brazil
Gin‐Fu Chen United States
Priya Raman United States
Yaqi Zhang China
Karthigayan Shanmugasundaram United States
Ruizheng Shi China
Qian Yu China
Shengnan Du
Citations per year, relative to Shengnan Du Shengnan Du (= 1×) peers Qian Yu

Countries citing papers authored by Shengnan Du

Since Specialization
Citations

This map shows the geographic impact of Shengnan Du's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shengnan Du with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shengnan Du more than expected).

Fields of papers citing papers by Shengnan Du

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shengnan Du. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shengnan Du. The network helps show where Shengnan Du may publish in the future.

Co-authorship network of co-authors of Shengnan Du

This figure shows the co-authorship network connecting the top 25 collaborators of Shengnan Du. A scholar is included among the top collaborators of Shengnan Du based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shengnan Du. Shengnan Du is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Qi, Yingqiu, Xi Yang, Yana Zhang, et al.. (2024). Targeted degradation of LRG1 to attenuate renal fibrosis. Asian Journal of Pharmaceutical Sciences. 19(4). 100941–100941. 8 indexed citations
2.
Zhuang, Xiaoyu, Jiaqi Zhang, Meng Li, et al.. (2023). Clinical characterization and proteomic profiling of lean nonalcoholic fatty liver disease. Frontiers in Endocrinology. 14. 1171397–1171397. 6 indexed citations
3.
Zhu, Furong, Tao Huang, Shengnan Du, et al.. (2023). Identification of LRG1 targeting peptide and its application in targeted imaging for breast cancer. Nano Research. 17(10). 9044–9051. 7 indexed citations
4.
Zhang, Yu, et al.. (2023). Highly efficient and cis-selective carbofunctionalization of internal alkynes catalyzed by palladium a-diimine complexes. Molecular Catalysis. 549. 113493–113493. 1 indexed citations
5.
Li, Fang, Shengnan Du, Jeffry Florian, et al.. (2022). Model‐Based Approach to Selecting Pegfilgrastim Dose for Pharmacokinetic and Pharmacodynamic Similarity Studies in Biosimilar Development. Clinical Pharmacology & Therapeutics. 113(1). 62–70. 1 indexed citations
6.
7.
Huang, Tao, Xianfu Sun, Yapeng Li, et al.. (2022). Peptide self-assembled nanomedicine induces antitumor immunity by blocking the PD-1/PD-L1 axis. Frontiers in Materials. 9. 2 indexed citations
8.
Ding, Jia-Hua, Yongjun Fang, Rongfu Zhou, et al.. (2022). Cord-Blood Engraftment Using an Enhanced Dual-Conditioning Regimen for Malignant Hematologic Diseases. Cell Transplantation. 31. 4211128094–4211128094.
9.
Zhang, Yongjun & Shengnan Du. (2022). Moral cleansing or moral licensing? A study of unethical pro-organizational behavior’s differentiating Effects. Asia Pacific Journal of Management. 40(3). 1075–1092. 12 indexed citations
10.
11.
Zhang, Changqing, Zhihong Zeng, Jiyong Zhang, et al.. (2021). Preclinical Characterization of the Selective JAK1 Inhibitor LW402 for Treatment of Rheumatoid Arthritis. Journal of Inflammation Research. Volume 14. 2133–2147.
12.
Du, Shengnan. (2021). Application of Learner-Centered Approach in College English Instruction in China: A Case Study. English Language Teaching. 14(10). 23–23. 5 indexed citations
13.
Hu, Cheng, Xiaoyu Zhuang, Jiaqi Zhang, et al.. (2021). Serum Metabolomics in Patients with Coexisting NAFLD and T2DM Using Liquid Chromatography-Mass Spectrometry. Laboratory Medicine. 53(4). 360–368. 1 indexed citations
14.
Xu, Hu, Shengnan Du, Qingwei Li, et al.. (2020). Endothelial cell prostaglandin E2 receptor EP4 is essential for blood pressure homeostasis. JCI Insight. 5(13). 27 indexed citations
15.
16.
Du, Shengnan, Jeffrey Sarver, Christopher Trabbic, et al.. (2018). 6-MOMIPP, a novel brain-penetrant anti-mitotic indolyl-chalcone, inhibits glioblastoma growth and viability. Cancer Chemotherapy and Pharmacology. 83(2). 237–254. 13 indexed citations
17.
Zhou, Xinrong, et al.. (2017). Differences in molecular regulation between osteochondroma and bizarre parosteal osteochondromatous proliferation. Molecular Medicine Reports. 16(1). 801–805. 2 indexed citations
18.
Trabbic, Christopher, et al.. (2016). Synthesis and biological evaluation of isomeric methoxy substitutions on anti-cancer indolyl-pyridinyl-propenones: Effects on potency and mode of activity. European Journal of Medicinal Chemistry. 122. 79–91. 30 indexed citations
19.
Gao, Min, Rong Cao, Shengnan Du, et al.. (2015). Disruption of prostaglandin E2 receptor EP4 impairs urinary concentration via decreasing aquaporin 2 in renal collecting ducts. Proceedings of the National Academy of Sciences. 112(27). 8397–8402. 56 indexed citations
20.
Wang, Chunjiong, Yujing Chi, Jing Li, et al.. (2013). FAM3A Activates PI3K p110α/Akt Signaling to Ameliorate Hepatic Gluconeogenesis and Lipogenesis. Hepatology. 59(5). 1779–1790. 98 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Qian Yu Breakdown of academic impact, for papers by Chakradhari Sharan Breakdown of academic impact, for papers by Hüseyin Sönmez Breakdown of academic impact, for papers by Antônio Ricardo de Toledo Gagliardi Breakdown of academic impact, for papers by Gin‐Fu Chen Breakdown of academic impact, for papers by Priya Raman Breakdown of academic impact, for papers by Yaqi Zhang Breakdown of academic impact, for papers by Karthigayan Shanmugasundaram Breakdown of academic impact, for papers by Ruizheng Shi
Rankless by CCL
2026